Clinical stage natural psychedelic drug development company supporting treatment of mental health conditions Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) has received a patent allowing it to extract and standardize natural psilocybin from the United States Patent and Trademark Office (UPTSO).
The company’s chief executive officer, Benjamin Lightburn, made this announcement on April 13 adding that this patent strengthens the patent portfolio of Filament Health.
“The issuance of Filament’s first US patent is a testament to the strength of our drug development platform,” said the CEO.
Back in August 2021, Filament Health was granted the first ever Canadian patent for extracting and standardizing natural psilocybin by a public company, this process is done by the company’s subsidiary, Psilo Scientific.
“Shepherding an application to issuance is different in every country, therefore having our IP validated by more than one government is evidence of our team’s talent for innovation by truly diverse criteria,” said the company’s director of intellectual property, Taran Grey.
